17 Consumer Groups and Unions Ask FTC to Block AbbVie's Acquisition of Allergan [The Motley Fool]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: The Motley Fool
17 Consumer Groups and Unions Ask FTC to Block AbbVie's Acquisition of Allergan The groups are worried about reduced competition if the merger goes through. Seventeen consumer groups and unions have again voiced their opposition to AbbVie 's ( NYSE:ABBV ) acquisition of Allergan ( NYSE:AGN ) in a letter to the Federal Trade Commission. The organizations, which represent over 10 million subscribers and members, originally raised concerns in September that the merger would harm competition. Since then, the FTC has requested the drugmakers divest themselves of a few products to reduce the anticompetitive nature of the deal. In the Crohn's disease and ulcerative colitis space, Allergan agreed to hand the rights to brazikumab back to AstraZeneca ( NYSE:AZN ) from which it had licensed the drug. Brazikumab is in mid-to-late stage clinical trials for the two diseases. Allergan also agreed to sell its gastrointestinal medication Zenpep to Nestle . The drug, which is used by patients who do
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis [Yahoo! Finance]Yahoo! Finance
- Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell ArteritisPR Newswire
- Big Growth Ahead: Biologic Drugs Market to Hit $823.4 Billion by 2028, Reveals BCC Research [Yahoo! Finance]Yahoo! Finance
- AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know [Yahoo! Finance]Yahoo! Finance
- 12 Best Dividend Stocks with High Upside Potential [Yahoo! Finance]Yahoo! Finance
ABBV
Earnings
- 2/2/24 - Beat
ABBV
Sec Filings
- 4/3/24 - Form 8-K
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- ABBV's page on the SEC website